Quetiapine add-on therapy improves the depressive behaviors and hippocampal neurogenesis in fluoxetine treatment resistant depressive rats

Behavioural Brain Research

Volumn 253, Issue , 2013, Pages 206-211

  Wang, Ying ^a   Chang, Ting ^b   Chen, Yun Chun ^a   Zhang, Rui Guo ^a   Wang, Hua Ning ^a   Wu, Wen Jun ^a   Peng, Zheng Wu ^a   Tan, Qing Rong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Chronic unpredictable mild stress; Hippocampus; Neurogenesis; Quetiapine; Treatment resistant depression

Indexed keywords

FLUOXETINE; QUETIAPINE;

ADD ON THERAPY; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; BEHAVIOR CHANGE; CELL PROLIFERATION; CONTROLLED STUDY; DEPRESSION; EXPERIMENTAL RAT; EXPERIMENTAL TEST; FORCED SWIMMING TEST; IMMUNOHISTOCHEMISTRY; MALE; NERVE CELL DIFFERENTIATION; NERVOUS SYSTEM DEVELOPMENT; NEWBORN; NONHUMAN; NOVELTY SUPPRESSED FEEDING TEST; PRIORITY JOURNAL; RAT; SUCROSE PREFERENCE TEST; TREATMENT RESISTANT DEPRESSION;

CHRONIC UNPREDICTABLE MILD STRESS; HIPPOCAMPUS; NEUROGENESIS; QUETIAPINE; TREATMENT RESISTANT DEPRESSION;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIMETABOLITES; ANTIPSYCHOTIC AGENTS; BROMODEOXYURIDINE; CELL COUNT; CELL PROLIFERATION; DEPRESSIVE DISORDER; DIBENZOTHIAZEPINES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EATING; ENVIRONMENT; FLUOXETINE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; MALE; NEUROGENESIS; RATS; RATS, SPRAGUE-DAWLEY; STRESS, PSYCHOLOGICAL; SUCROSE; SWIMMING; TISSUE FIXATION;

EID: 84881330023     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2013.07.021     Document Type: Article

References (39)

1. Moussavi S., Chatterji S., Verdes E., Tandon A., Patel V., Ustun B. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007, 370:851-858.
2. Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study. Lancet 1997, 349:1498-1504.
3. Chapman D.P., Perry G.S. Depression as a major component of public health for older adults. Preventing Chronic Disease 2008, 5:A22.
4. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 2006, 163:28-40.
5. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. American Journal of Psychiatry 2006, 163:1905-1917.
6. Anderson I.M., Ferrier I.N., Baldwin R.C., Cowen P.J., Howard L., Lewis G., et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. Journal of Psychopharmacology 2008, 22:343-396.
7. Freemantle N., Anderson I.M., Young P. Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis. The British Journal of Psychiatry: The Journal of Mental Science 2000, 177:292-302.
8. Conwell Y., Suicide Brent D., Aging I. Patterns of psychiatric diagnosis. International Psychogeriatrics 1995, 7:149-164.
9. Kochanek K.D., Murphy S.L., Anderson R.N., Scott C. Deaths: final data for 2002. National Vital Statistics Reports 2004, 53:1-115.
10. Weissman M.M., Bland R.C., Canino G.J., Greenwald S., Hwu H.G., Joyce P.R., et al. Prevalence of suicide ideation and suicide attempts in nine countries. Psychological Medicine 1999, 29:9-17.
11. Petersen T., Gordon J.A., Kant A., Fava M., Rosenbaum J.F., Nierenberg A.A. Treatment resistant depression and axis I co-morbidity. Psychological Medicine 2001, 31:1223-1229.
12. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nature Reviews Neuroscience 2006, 7:137-151.
13. Mathew S.J., Manji H.K., Charney D.S. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology 2008, 33:2080-2092.
14. Chen J., Gao K., Kemp D.E. Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Current Opinion in Psychiatry 2011, 24:10-17.
15. Papakostas G.I., Shelton R.C., Smith J., Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. Journal of Clinical Psychiatry 2007, 68:826-831.
16. Anderson I.M., Sarsfield A., Haddad P.M. Efficacy, safety and tolerability of quetiapine augmentation in treatment resistant depression: an open-label, pilot study. Journal of Affective Disorders 2009, 117:116-119.
17. Suppes T., Datto C., Minkwitz M., Nordenhem A., Walker C., Darko D. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. Journal of Affective Disorders 2010, 121:106-115.
18. Pae C.U., Sohi M.S., Seo H.J., Serretti A., Patkar A.A., Steffens D.C., et al. Quetiapine XR: current status for the treatment of major depressive disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010, 34:1165-1173.
19. Sagud M., Mihaljevic-Peles A., Muck-Seler D., Jakovljevic M., Pivac N. Quetiapine augmentation in treatment-resistant depression: a naturalistic study. Psychopharmacology 2006, 187:511-514.
20. Baune B.T., Caliskan S., Todder D. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Human Psychopharmacology 2007, 22:1-9.
21. Devarajan S., Ali J., Dursun S.M. Quetiapine plus SSRI in treatment-resistant depression: possible mechanisms. Psychopharmacology (Berl) 2006, 185:402-403.
22. Doree J.P., Des Rosiers J., Lew V., Gendron A., Elie R., Stip E., et al. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Current Medical Research and Opinion 2007, 23:333-341.
23. Blier P., Blondeau C. Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. Journal of Affective Disorders 2011, 128(Suppl 1):S3-S10.
24. Jensen N.H., Rodriguiz R.M., Caron M.G., Wetsel W.C., Rothman R.B., Roth B.L. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008, 33:2303-2312.
25. Olver J.S., Ignatiadis S., Maruff P., Burrows G.D., Norman T.R. Quetiapine augmentation in depressed patients with partial response to antidepressants. Human Psychopharmacology 2008, 23:653-660.
26. Burghardt N.S., Park E.H., Hen R., Fenton A.A. Adult-born hippocampal neurons promote cognitive flexibility in mice. Hippocampus 2012, 22:1795-1808.
27. Luo C., Xu H., Li X.M. Quetiapine reverses the suppression of hippocampal neurogenesis caused by repeated restraint stress. Brain Research 2005, 1063:32-39.
28. Wang Y., Yang F., Liu Y.F., Gao F., Jiang W. Acetylsalicylic acid as an augmentation agent in fluoxetine treatment resistant depressive rats. Neuroscience Letters 2011, 499:74-79.
29. Willner P., Towell A., Sampson D., Sophokleous S., Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology (Berl) 1987, 93:358-364.
30. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends in Pharmacological Sciences 2002, 23:238-245.
31. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.P., Bai G., et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. Journal of Clinical Investigation 2005, 115:3104-3116.
32. Porsolt R.D.B., Jalfre A.M. Behavioral despair in mice: a primary screening test for antidepressants. Archives Internationales de Pharmacodynamie et de Therapie 1977, 229:327-336.
33. Bergstrom A., Jayatissa M.N., Thykjaer T., Wiborg O. Molecular pathways associated with stress resilience and drug resistance in the chronic mild stress rat model of depression: a gene expression study. Journal of Molecular Neuroscience 2007, 33:201-215.
34. Bodnoff S.R., Suranyi-Cadotte B., Aitken D.H., Quirion R., Meaney M.J. The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology 1988, 95:298-302.
35. Alonso R.G., Pavone G., Stemmelin G., Le Fur J., Soubrie G.P. Blockade of CRF(1) or V(1b) receptors reverses stress-induced suppression of neurogenesis in a mouse model of depression. Molecular Psychiatry 2004, 9(278-86):24.
36. Orsetti M., Canonico P.L., Dellarole A., Colella L., Di Brisco F., Ghi P. Quetiapine prevents anhedonia induced by acute or chronic stress. Neuropsychopharmacology 2007, 32:1783-1790.
37. Chertkow Y., Weinreb O., Youdim M.B., Silver H. Molecular mechanisms underlying synergistic effects of SSRI-antipsychotic augmentation in treatment of negative symptoms in schizophrenia. Journal of Neural Transmission 2009, 116:1529-1541.
38. Duman R.S. Depression: a case of neuronal life and death. Biological Psychiatry 2004, 56:140-145.
39. Santarelli L.S., Gross M., Surget C., Battaglia A., Dulawa F., Weisstaub S., et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003, 301:805-809.